文献速递心外重症与机械循环支持

Custodiol-N与Custodiol在心脏移植中的非劣效性随机对照试验

Custodiol-N versus Custodiol: Results from a prospective noninferiority randomized single blind, multicenter phase 3 trial in patients undergoing heart transplantation.
PubMed 文献 · J Heart Lung Transplant · 2025-04-23

这项前瞻性、随机、单盲、多中心、非劣效性3期试验在奥地利和德国的3个中心开展,纳入105例心脏移植患者,比较Custodiol-N与Custodiol保存液的效果。主要终点为主动脉开放后4至168小时肌酸激酶(CK-MB)峰值,非劣效界值为30%。结果显示Custodiol-N组CK-MB峰值非劣效于Custodiol组(p<0.0001),患者1年生存率相当,安全性事件分布均衡。

要点

  • Custodiol-N在心脏移植中主要终点CK-MB峰值非劣效于Custodiol。
  • 两组1年患者生存率相当(90.4% vs 88.7%)。
  • Custodiol组原发移植物衰竭发生率和ICU中位住院时间更高。

核心结论

  • Custodiol-N安全、非劣效,并提供与Custodiol相似的心脏移植物保护。

研究设计与样本

  • 前瞻性、随机、单盲、多中心、非劣效性3期试验,在奥地利和德国3个中心开展,共105例随机患者接受Custodiol(n=52)或Custodiol-N(n=53)保存的心脏。

主要发现

  • 平均CK-MB峰值Custodiol组为176.94 ± 189.61 U/L,Custodiol-N组为130.51 ± 69.60 U/L,非劣效性p<0.0001。
  • 移植后1年患者生存率Custodiol组为90.4%,Custodiol-N组为88.7%。
  • Custodiol组原发移植物衰竭发生率和ICU中位住院时间更高。
  • 安全性评估显示不良事件分布均衡。

关键数值与推荐

  • 主要终点为主动脉开放后4至168小时CK-MB峰值,非劣效界值为30%。

临床怎么用

  • Custodiol-N可作为心脏移植中Custodiol的替代保存液,提供相似的心脏移植物保护。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Custodiol is a well-established preservation solution for organ transplantation and was the basis for the development of Custodiol-N to improve graft preservation. Previous results in coronary artery bypass graft surgery have shown effective cardiac protection without safety concerns. This study aimed to evaluate the safety and ability of Custodiol-N to preserve cardiac grafts for heart transplantation. METHODS: This prospective, randomized, single-blind, multicenter, noninferiority study was conducted at three centers in Austria and Germany. The primary end-point was creatine kinase (CK-MB) peak value from 4 to 168 hours after opening of the aortic cross clamp, with a 30% noninferiority margin. Key secondary efficacy end-points include patient and graft survival, incidence of primary graft failure, or length of stay in the intensive care unit. The primary and secondary end-points were analyzed in both the treated and per protocol populations. RESULTS: A total of 105 randomized patients received Custodiol (n = 52) or Custodiol-N (n = 53) preserved hearts. Average donor age and ischemic times were comparable. Average CK-MB peak values were 176.94 ± 189.61 U/L for the Custodiol versus 130.51 ± 69.60 U/liter for the Custodiol-N group (p-value for noninferiority of Custodiol-N by 30% <0.0001). Patient survival was comparable 1-year post transplantation (90.4% for Custodiol versus 88.7% for Custodiol-N). The incidence of primary graft failure and median length of intensive care unit stay were higher for Custodiol group. Safety assessment showed evenly distributed adverse events. CONCLUSIONS: This study shows that Custodiol-N is safe, noninferior, and provides similar cardiac graft protection as the established Custodiol solution.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Aliabadi-Zuckermann A, Osorio-Jaramillo E, Knosalla C, et al. Custodiol-N versus Custodiol: Results from a prospective noninferiority randomized single blind, multicenter phase 3 trial in patients undergoing heart transplantation. J Heart Lung Transplant. 2025. PMID: 40280454. doi:10.1016/j.healun.2025.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。